STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE

Kowa Research Europe Ltd.0 个研究点目标入组 300 人开始时间: 2005年12月29日最近更新: 2012年4月3日

适应症

试验速览

阶段: 不适用
状态: 进行中（未招募）
发起方: Kowa Research Europe Ltd.
入组人数: 300

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: All

入选标准

•1. Males and females (age range 18-75 years);
•2. Non-pregnant, non-lactating females. Women of child bearing potential are allowed to enter the study ONLY if they use sustained contraceptive preparations (e.g., implants or intramuscular [IM] injections) or comply with an approved mechanical contraceptive method.
•3. At least two cardiovascular disease risk factors have to be present:
•- Cigarette smoking;
•- Hypertension (blood pressure =140/90 mm Hg or on antihypertensive medication);
•- Low HDL-C (<1.0 mmol/L [40 mg/dL]);
•- Family history of premature (CHD in male first-degree relative <55 years of age; CHD in female first-degree relative <65 years of age)
•Note: If HDL-C is >60 mg/dL at Visit 3 (Week -1) or Visit 3A (if applicable) then the number of risk factors will be reduced by 1.
•- Age (men =45 years, women =55 years).
•4. Patients who are eligible and able to participate in the study and who have given informed consent after the purpose and nature of the investigation has been explained to them;
•5. In order to qualify for randomization at Visit 4 (Week 0), patients must have been following a fat and cholesterol restrictive diet as advised by the EAS during the dietary stabilization lead-in period (i.e. for at least 8 weeks for those patients previously taking lipid lowering medication and at least 6 weeks for those not previously taking lipid lowering medication). Patients must also agree not to eat grapefruit or drink grapefruit juice for the duration of the study;
•6. In order to qualify for randomization at Visit 4 (Week 0), patients must present with primary hypercholesterolemia or combined dyslipidemia, as defined by elevated plasma LDL C (LDL C =3.4 mmol/L [130 mg/dL] =5.7 mmol/L [220 mg/dL]) despite dietary therapy and elevated TG levels of =4.6 mmol/L (400 mg/dL) at 2 visits during the dietary lead-in period. If these criteria are not satisfied at Visit 2 (Week –2) and Visit 3 (Week –1), or if the LDL C concentration of the lower qualifying specimen differs by =15% from the higher qualifying specimen, 1 additional lipid sample will be permitted for both variables 1 week after Visit 3 (Visit 3A) to enable the patient to qualify for randomization
•7. Patients have to agree to be available for every clinic visit, which will occur in the morning.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

排除标准

•1. Homozygous familial hypercholesterolemia (heterozygous component of familial hypercholesterolemia is acceptable for inclusion);
•2. Any conditions which may cause secondary dyslipidemia.
•3. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of any drug.
•4. Any history of pancreatic injury or pancreatitis, or impaired pancreatic function/injury as indicated by abnormal lipase or amylase;
•5. Liver injury, imparied renal function, uncontrolled diabetes mellitus
•6. Current obstruction of the urinary tract or difficulty in voiding due to mechanical as well as inflammatory conditions, which is likely to require intervention during the course of the study or is regarded as clinically meaningful by the investigator;
•7. Serum CK levels >5 x ULRR over the lead in period. For patients with unexplained serum CK >5 x ULRR at Visit 1 or 2, a repeat CK >5 x ULRR in the absence of conditions explaining the CK elevation is exclusionary;
•8. Uncontrolled hypothyroidism.
•9. Any severe acute illness or severe trauma in the last 3 months prior to Visit 1 (Week -8/-6);
•10. Major surgery, during the 3 months prior to Visit 1 (Week -8/-6);
•11. Significant CVD prior to randomization, such as myocardial infarction, coronary or peripheral artery angioplasty, bypass graft surgery or severe or unstable angina pectoris within the last 3 months;
•12. Evidence of symptomatic heart failure (New York Heart Association [NYHA] class III or IV), gross cardiac enlargement (cardiothoracic ratio >0.5); significant heart block or cardiac arrhythmias.
•13. Left ventricular (LV) ejection fraction <0.25;
•14. History of symptomatic cerebrovascular disease including cerebrovascular hemorrhage, transient ischemic attack or carotid endarterectomy within 1 month prior to randomization;
•15. Any other medical or surgical conditions at the discretion of the investigator which place the patient at higher risk derived from his/her participation in the study, which could confound the result of the study, or are likely to prevent the patient from complying with the requirements of the study or completing the study period;
•16. Known Human Immunodeficiency Virus (HIV) infection;
•17. Poorly controlled or uncontrolled hypertension.
•18. Prior or current known muscular or neuromuscular disease of any type;
•19. Current active neoplastic disease or patients who may require antineoplastic treatment during the course of the study.
•20. Within the last 2 years, a history of drug abuse or continuous consumption of more than 65 mL pure alcohol per day
•21. Exposure to any investigational new drug within 30 days of study entry (Visit 1/Week –8/-6) or ingestion of any drug known to be toxic to a major organ system (such as those producing blood dyscrasias, nephrotoxicity, hepatotoxicity or neurotoxicity) within 12 weeks prior to the study entry (Visit 1/Week –8/-6);
•22. Current or recent (within 4 weeks of Visit 1 [Weeks –8/-6]) use of supplements known to alter lipid metabolism e.g. soluble fibers (including >2 teaspoons Metamucil or psyllium containing supplement per day), or other dietary fiber supplements, fish oils, sterol/stanol products, or others at the discretion of the investigator;
•23. History of hypersensitivity reactions to other HMG-CoA reductase inhibitors;
•24. Any concomitant medication not permitted by this protocol (see Section 4.5.5, Concomitant Therapy);
•25. History of being resistant to lipid-lowering m

研究者

发起方

Kowa Research Europe Ltd.

相似试验

进行中（未招募）

不适用

STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASEHypercholesterolemia or Combined Dyslipidemia and 2 or more risk factors for coronary heart disease (CHD)MedDRA version: 7.1Level: LLTClassification code 10020604

EUCTR2005-001037-15-SEKowa Research Europe Ltd.300

进行中（未招募）

不适用

EUCTR2005-001037-15-DKKowa Research Europe Ltd.300

进行中（未招募）

1 期

STUDY OF PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP- TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIA AND 2 OR MORE RISK FACTORS FOR CORONARY HEART DISEASE

EUCTR2005-001037-15-ESKowa Research Europe Ltd.150

进行中（未招募）

不适用

STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG (FOLLOWING UP-TITRATION) IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIAPRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIAMedDRA version: 7.1Level: LLTClassification code 10020604

EUCTR2005-001033-15-GBKowa Research Europe Ltd.800

进行中（未招募）

不适用

STUDY OF PITAVASTATIN 2 MG vs. SIMVASTATIN 20 MG AND PITAVASTATIN 4 MG vs. SIMVASTATIN 40 MG FOLLOWING UP-TITRATION IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIAPRIMARY HYPERCHOLESTEROLEMIA OR COMBINED DYSLIPIDEMIAMedDRA version: 6.1Level: PTClassification code 10020603

EUCTR2005-001033-15-ITKOWA RESEARCH EUROPE LTD800